Gencurix's Study Explores the Difference between GenesWell BCT...
SEOUL, South Korea, Aug.14, 2019/PRNewswire-AsiaNet/-- Gencurix, Inc., a molecular diagnostics company, announced the publication of a new study on Frontiers in Oncology comparing GenesWell(TM) BCT, a prognostic multigene test, with Genomic Health's Oncotype DX in patients with early-stage breast canc...
Authors: LATEST ASIANET NEWS RELEASES